Introduction
New insights in the biology of gastrointestinal stromal tumors (GIST) have triggered remarkable clinical progress in a disease that had been refractory to all systemic therapies. The KIT or platelet-derived growth factor receptor alpha gene (PDGFRA) receptor tyrosine kinases are constitutively activated by gain-of-function mutations in most GISTs, and these mutations are early events in GIST oncogenesis (Hirota et al., 1998; Corless et al., 2002) . Clinical responses to the imatinib (IM) kinase inhibitor are seen in B80% of patients with metastatic GIST (B50% partial response, B30% stable disease), resulting in a 3-year survival rate of 69-74% (Demetri et al., 2002; Verweij et al., 2004) . By contrast, the median survival for metastatic GIST in the preimatinib era was 19 months (Dematteo et al., 2000) .
However, therapeutic kinase inhibition by imatinib is not uniformly successful. GIST patients (10-20%) exhibit primary resistance to imatinib and, furthermore, imatinib response rates and durations vary depending on the exonic location of KIT mutations in GIST (Heinrich et al., 2003) . In addition, there is evidence that imatinib exhibits more cytostatic than cytotoxic effects, as complete responses to imatinib in metastatic GIST are rare (p5%) and most responding patients develop secondary resistance (Verweij et al., 2004) . Notably, a subset of viable tumor cells can be found in most patients who undergo GIST resections during imatinib therapy, indicating that imatinib-resistant clones are present in most GISTs (Bauer et al., 2005a) .
The mechanisms of primary and secondary imatinib resistance in GIST are incompletely understood, but most imatinib-resistant GISTs continue to express strongly activated KIT (unpublished data). Therefore it can be assumed that the KIT signaling pathway generally remains a useful therapeutic target at the time of GIST clinical progression (Fletcher et al., 2003) . Most patients with secondary imatinib resistance develop additional point mutations, in the KIT kinase domains (Fletcher et al., 2003; Debiec-Rychter et al., 2005; Heinrich et al., 2006) . These secondary imatinibresistant mutations involve various conserved amino acids in the KIT kinase domain, and can vary between different progressing metastases in each patient (Antonescu et al., 2005; Heinrich et al., 2006; Wardelmann et al., 2006) . The multitargeted KIT inhibitor sunitinib has proven effective in a subset of patients with imatinib-resistant GIST while other novel inhibitors of KIT such as PKC412 or BMS-354825 show promising preclinical activity against certain imatinib-resistant mutations in GIST (Shah et al., 2004; Debiec-Rychter et al., 2005; Demetri et al., 2006) . However, none of these inhibitors are expected to be effective in inhibiting all the known imatinib-resistant mutations.
We have shown that primary GISTs with oncogenic KIT and PDGFRA mutations have activation of the MAPK/ERK kinase/mitogen-activated protein kinase (MEK/MAPK) and phosphatidyl-inositol-3-kinase (PI3-K)/AKT pathways, accompanied by relatively low-level STAT1 and STAT3 activation (Duensing et al., 2004) . The oncogenic KIT signaling mechanisms varied depending on the exact location and type of the oncogenic KIT mutation in a given GIST (Duensing et al., 2004) . The studies herein characterize oncogenic KIT signaling pathways in a panel of molecularly characterized human GIST cell lines, and demonstrate which pathways might be particularly relevant for therapeutic intervention.
Results
Effects of imatinib on KIT, AKT and MAPK activation in GIST cell lines KIT expression was equally strong in GIST 882, GIST430 and GIST48 but was not demonstrable in GIST62 (Figure 1 ). KIT activation was three-to sixfold higher in GIST430 and GIST48 compared to GIST882 ( Figure 1) ; GIST 62 showed no demonstrable KIT activation (Figure 1 ). After treatment with 1 mM imatinib, residual KIT activation was 6-and 2.8-fold higher in GIST430 and GIST48, respectively, compared to GIST882 (Figure 1) . Similarly, 1 mM imatinib treatment resulted in complete inhibition of the KITdependent signaling intermediates, AKT and MAPK, in GIST882 (Figure 1 ), but not in GIST430 and GIST48 where phospho-AKT (S473) expression persisted at 33 and 10% of baseline levels, respectively, and phospho-MAPK (T202/Y204) expression persisted at 13 and 15% of baseline levels, respectively (Figure 1) . Notably, 1 mM imatinib treatment did not inhibit AKT or MAPK in the KIT-negative GIST62 cell line, underscoring that imatinib-mediated AKT and MAPK inhibition is KITdependent in GIST.
Signaling perturbations after MAPK, PI3-K and mTOR inhibition in GIST cell lines Cell signaling roles of MAPK, PI3-K and mammalian target of rapamycin (mTOR) were evaluated by immunoblotting in the imatinib-sensitive and imatinibresistant cell lines. MEK1/MEK2 inhibition by 10 mM U0126 completely inhibited MAPK phosphorylation in all GIST cell lines (Figure 1 ). MAPK inhibition was accompanied by 60-95% inhibition of S6 phosphorylation (Figure 2 ). PI3-K inhibition by 50 mM LY294002 substantially inhibited AKT, S6 and 4EBP-1 phosphorylation in all GIST cell lines (Figures 1 and 2) . mTOR inhibition by the rapamycin derivative, RAD001/ everolimus, abolished S6 phosphorylation (Figure 2) . Unexpectedly, although 4EBP1 phosphorylation was completely lost, in all GIST cell lines, after treatment with the LY294002 PI3-K inhibitor, KIT inhibition by imatinib and mTOR inhibition by RAD001 resulted in only 0-50% decrease in 4EBP1 phosphorylation (Figure 2 ).
Effects of KIT inhibition on STAT activation
Signal transducer and activator (STAT) proteins have been implicated in oncogenic signaling by KIT and other receptor tyrosine kinase proteins (Frank 1999; Linnekin 1999) . We previously reported expression of STAT1 and STAT3, but not STAT5, in most primary GIST, although STAT1 and STAT3 activation varied considerably in these tumors (Duensing et al., 2004) . In the present study all GIST lines showed expression of Figure 1 Effects of kinase inhibitors on KIT, MAPK and AKT phosphorylation in imatinib-sensitive (GIST882) and imatinibresistant (GIST48, GIST430 and GIST62) cell lines. The GIST cells were treated for 6 h with inhibitors of KIT (imatinib/IM, 1 mM), MEK1/MEK2 (U0126, 10 mM), PI3-K (LY294002, 50 mM), mTOR (RAD001, 20 nM) and PLCg (D609, 10 mM). An internal standard lane (not shown) was used to obtain equivalent exposures for all immunoblots. The combination inhibitor studies were also performed using 1 mM imatinib. GIST882 was included, as a positive control for KIT expression, in immunoblots of the KITnegative GIST62 cell line.
KIT oncogenic signaling in imatinib-resistant GIST S Bauer et al activated STAT1 and STAT3. Inhibition of KIT by imatinib reduced STAT1 (Y701) and STAT3 (Y705) phosphorylation in GIST882 by 75-100% ( Figure 3 ). In GIST48 and GIST430, respectively, activation of STAT1 decreased 60 and 80% and activation of STAT3 decreased 20 and 50% upon inhibition of KIT. By contrast, there was no STAT inactivation in imatinibtreated KIT-negative GIST62 cells (Figure 3 ). In all, these findings indicate that STAT1 and STAT3 activation are partially KIT dependent in both imatinibsensitive and imatinib-resistant GIST models. Similarly, STAT activation was partially dependent (30-60%) on MAPK and PI3-K in all KIT-expressing cell lines ( Figure 3 ).
Effects of JAK inhibition on STAT activation
STAT activation can result from ligand-mediated mechanisms involving a number of cell surface receptors. In general, these mechanisms involve dimerization and phosphorylation of JAK proteins, which in turn phosphorylate STAT proteins. We therefore evaluated the effects of JAK inhibitors in the GIST cell line models.
JAK-inhibitor 1, a highly specific inhibitor of JAK1, JAK2, JAK3 and Tyk2, inhibited STAT1 and STAT3 phosphorylation substantially in GIST48 and GIST62 and by 80% in GIST430 when used at the 1 mM (Figure 4) . Unexpectedly, however, treatment of GIST882 cells with 0.1 and 1 mM JAK-inhibitor 1 resulted in 1.7-and 1.3-fold increases, respectively, in STAT3 phosphorylation. Treatment with the JAK2 inhibitor, AG490, resulted in partial inhibition of STAT1 and STAT3 phosphorylation in all GIST cell lines ( Figure 4 ).
Effects of PLCg inhibition on KIT-oncogenic signaling and PKCy
Ligand-mediated activation of wild-type KIT by stem cell factor has been shown to activate PLCg (Linnekin 1999) , and PLCg activation might regulate protein kinase C (PKC) signaling through provision of PKC cofactors. We therefore evaluated the effects of PLCg inhibition on phosphorylation of the highly GISTspecific PKC family member, PKCy. PKCy activation and phosphorylation were demonstrated in GIST882, GIST430 and GIST48 but not in the KIT-negative GIST62 line (Figure 2 ). However, treatment with the PLCg inhibitor, D609, did not alter phosphorylation of PKCy, nor any of the other signaling intermediates assayed in this study (Figures 1-3 ).
Comparative effects of KIT, MEK1/2, PI3-K, mTOR, PLCg and JAK inhibition on GIST cell proliferation and apoptosis The biological relevance of MEK, PI3-K, mTOR, PLCg and JAK signaling in imatinib-resistant GIST was evaluated by determining consequences of kinase Effects of JAK inhibitors on KIT, MAPK and AKT phosphorylation in imatinib-sensitive (GIST882) and imatinib-resistant (GIST48, GIST430 and GIST62) cell lines. The GIST cells were treated for 6 h with inhibitors of JAK (JAK-inhibitor, 1: 100 and 1000 nM; AG490, 10 and 50 mM). GIST882 was included, as a positive control for KIT expression, in immunoblots of the KIT-negative GIST62 cell line and the U266 myeloma cell line. U266 myeloma cells are a positive control for JAK-dependent STAT1 and STAT3 phosphorylation.
KIT oncogenic signaling in imatinib-resistant GIST S Bauer et al GIST882 but not in GIST48, GIST430 and GIST62 ( Figure 6 ). PI3-K inhibition by LY294002 markedly decreased cell proliferation in all GIST cell lines ( Figure 5 ). Indeed, the antiproliferative effects of PI3-K inhibition were substantially greater than those accompanying imatinib treatment (1 mM) in GIST430, GIST48 and GIST62 where PI3-K inhibition resulted in 50, 74 and 40%, reductions in proliferation, respectively (Table 1) . PI3-K inhibition resulted in three-to fourfold increased caspase activity in the imatinib-resistant GIST lines, and 1.6-fold increased caspase activity in GIST 882. MEK and mTOR inhibition were associated with moderate antiproliferative effects in GIST882 (44 and 25% reductions in proliferation, respectively) but only minor effects (5-20% reductions in proliferation) in the imatinib-resistant GIST lines (Table 1) . MEK and mTOR inhibition were not accompanied by substantial caspase activation in any of the GIST lines ( Figure 6 ). PLCg inhibition by D609 did not affect cell proliferation or caspase activation in any cell line (Figures 5 and 6 ). Pan-JAK inhibition by treatment with JAK-inhibitor 1 (0.1 or 1 mM) for 3 days did not inhibit proliferation in any of the GIST lines (Supplementary Figure 1) . On the contrary, a 26% increased proliferation was seen in GIST882 after treatment with 1 mM JAK-inhibitor 1. JAK inhibition did not induce caspase activation in any of the GISTs (Figure 6 ).
Potential synergies for inhibition of KIT and downstream signaling intermediates were evaluated by treating the GIST lines with 250 nM imatinib in combination with the downstream kinase inhibitors. Additive effects were observed for imatinib and RAD001, where GIST882 proliferation was inhibited by 20, 55 and 86 after treatment with RAD001, imatinib and RAD001 þ imatinib, respectively, ( Figure 5 ). Additive effects were also seen with imatinib and both LY294002 and U0126, in that GIST882 proliferation was inhibited by 62% with LY294002 alone, 55% with U0126 alone, 85% with LY294002 þ imatinib and 79% with U0126 þ imatinib ( Figure 5 ). Additive effects were likewise seen for the combination of imatinib and AG490, in GIST48, with proliferation reduced by 35% after imatinib alone, 32% after AG490 and 65% after AG490 þ imatinib ( Figure 5 ). Figure 5 Proliferation response was determined after treatment of imatinib-sensitive (GIST882) and imatinib-resistant GIST cell lines with kinase inhibitors. Cells were treated with inhibitors (see Figure 1 legend ) for 72 h, and cell viability was assayed using the CellTiter-Glo ATP-based luminescence assay. The data were normalized to dimethyl sulfoxide (DMSO)-only controls, and represent the mean values (7s.d.) of quadruplicate cultures before (day 0) and after the inhibitor treatments. Combination inhibitor studies were performed using 0.25 mM imatinib.
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Discussion
Although more than 80% of inoperable GIST patients have dramatic clinical benefits from imatinib, most of these patients will eventually progress. Figure 6 Apoptotic response was determined by measuring caspase activation after treatment of imatinib-sensitive (GIST882) and imatinib-resistant GIST cell lines with kinase inhibitors of KIT, KIT-dependent signaling intermediates and JAK. Cells were treated with inhibitors for 24 h. Caspase-3 and -7 activity was assayed using the Caspase-Glo luminescence assay and data represent the mean values (7s.d.) of quadruplicate cultures. Combination inhibitor studies were performed using 0.25 mM imatinib. KIT oncogenic signaling in imatinib-resistant GIST S Bauer et al KIT-depending signaling intermediates are needed to overcome the problem of resistance to KIT kinase inhibitors. Most KIT imatinib-resistant mutations, in GIST, are located in the split kinase domain (Debiec-Rychter et al., 2005) , but it has been unclear whether these secondary mutations hyperactivate KIT or merely block imatinib effects. Our studies show that the GIST430 and GIST48 cell lines, both of which have double KIT mutations involving the juxtamembrane and kinase domains, have three-to sixfold stronger KIT activation compared to the GIST882 cell line, which has a single KIT mutation. This evidence of KIT hyperactivation in imatinib-resistant GIST is particularly dramatic in that GIST882 cells have a homozygous KIT mutation with two copies per cell of the mutant KIT locus and therefore show stronger KIT activation than most primary, untreated, GISTs (Bauer and Fletcher, data not shown). KIT autophosphorylation in GIST430 and GIST48 was accompanied by strong and KIT-dependent MAPK and AKT activation (Figure 1 ). Additional evidence that MAPK and AKT remain KIT-dependent in imatinib-resistant GIST has been obtained by shRNA knockdown of oncogenic KIT expression in GIST430 (Heinrich et al., 2006) . We have observed oncogenic kinase hyperactivation not only in imatinib-resistant GIST cell lines but also in biopsies from patients with imatinib-resistant GIST (Bauer and Fletcher, data not shown) which consistently have stronger KIT and AKT activation than biopsies from patients with primary GIST lacking secondary KIT mutations.
Although 1 mM imatinib treatment resulted in partial KIT inhibition in the imatinib-resistant GIST430 and GIST48 cell lines (Figure 1 ), nonetheless the postimatinib KIT phosphorylation levels were 2.8-to 6-fold higher than in GIST882, resulting in residual activation of MAPK and AKT. These findings demonstrate that resistance to imatinib is not absolute and may vary depending on the type of resistance mutation. GIST proliferation and survival is presumably determined by the absolute levels of KIT activation after imatinib treatment, and we propose that imatinib resistance, in the face of secondary KIT mutations, results both from intrinsic resistance -which varies amongst mutationsand from the challenge of reducing KIT hyperactivation below thresholds needed to support oncogenic survival and proliferation signaling through pathways, such as PI3-K/AKT and MEK/MAPK. This model of variable imatinib effects -even in the face of KIT-resistant mutations -may explain why GIST progression occurs late (median progression-free survival >18 months) in most patients responding to imatinib, and why imatinib rarely induces complete responses. In particular, whereas some KIT double mutants may be inhibited sufficiently to result in partial proliferation arrest, residual survival signaling, for example via PI3-K/ AKT, might ensure persistence of a subset of the GIST cells. This hypothesis is supported by studies of GIST imatinib-resistant KIT mutants after transient expression in a Chinese hamster ovary cell background (Heinrich et al., 2006) . Interestingly, the KIT-negative GIST62 cell line shows activation of the same proliferation and survival signaling intermediates that are KIT dependent in the GIST882, GIST430 and GIST48 cell lines (Figure 1 ). These findings suggest that a novel oncogenic mechanism has supplanted the KIT oncogenic role in GIST62. GIST62 was derived from a primary GIST with a homozygous KIT exon 11 mutation and despite retaining this KIT mutation in all cells expresses KIT protein at very low levels. The GIST62 cell line model may be relevant to clinical GISTs, where approximately 15% of KIT-positive GISTs lose KIT expression at time of clinical progression during imatinib therapy (Fletcher et al., 2003; Debiec-Rychter et al., 2005; Bauer et al., 2005a) . These findings underscore the considerable therapeutic potential of drugs targeting key signaling intermediates downstream of KIT.
The PI3-K/AKT pathway is essential to oncogenic signaling in KIT-mutant acute myeloid leukemia (Cammenga et al., 2005) , KIT-mutant mast cell disease (Shivakrupa et al., 2003) , and GIST murine models (Rossi et al., 2006) and our studies indicate a key role, as well, in imatinib-resistant GIST. mTOR, which is strongly activated by PI3-K pathways, has been evaluated as a clinical target, because the mTOR inhibitors rapamycin, CCI779 and RAD001 have an acceptable toxicity profile in vivo, compared to highly toxic PI3-K inhibitors. Our present studies shed additional light on KIT/PI3-K/AKT pathway activation mechanisms in GIST (Figures 1 and 2) . KIT inhibition resulted in substantial AKT and S6 deactivation in the imatinib-resistant GIST430 and GIST48, whereas 4EBP1 was unaffected. By contrast, PI3-K inhibition (by LY294002) inactivated AKT, S6 and 4EBP1 whereas mTOR inhibition (by RAD001) inactivated S6K but not 4EBP1. These findings underscore that modulations of PI3-K pathway signaling are unpredictable and 'nonlinear', and depend on cell context. Hence, our observations in GIST are different from those reported in CML models, where synergies have been postulated for imatinib and rapamycin (Mohi et al., 2004) based on rapamycin-mediated 4EBP1 inactivation. These differences are not unprecedented, in that rapamycin has been shown to differentially effect mTOR signaling in various mammalian cells, and 4EBP1 phosphorylation can be partially rapamycin insensitive.
As expected, imatinib showed only minor antiproliferative activity in the GIST430 and GIST48 cell lines (established from patients with imatinib-resistant GIST). Furthermore, imatinib induced almost no apoptosis in these cell lines (Figure 6 ). In contrast, PI3-K inhibition (by LY294002) showed strong antiproliferative properties (40-75% inhibition of proliferation) as well as increased apoptosis (three-to fourfold) in the imatinib-resistant GISTs (Figures 5 and 6 ). mTOR inhibition resulted in minor antiproliferative (5-20% inhibition) effects and no proapoptotic activity in the GIST cell lines (Figures 5 and 6 ). Additive effects with imatinib were seen with mTOR inhibition in GIST882, but not in GIST430 or GIST48, suggesting that combined therapeutic inhibition of KIT and mTOR might be particularly effective in patients whose GISTs remain imatinib sensitive.
In keeping with our findings in primary GIST (Duensing et al., 2004) , we observed MAPK activation in all GIST cell lines, including the KIT-negative GIST62. However, MAPK inhibition by U0126 showed inconsistent effects on proliferation (40% inhibition in GIST882, 5-20% inhibition in GIST430 and GIST48) and no effects on apoptosis, suggesting that MEK/ MAPK might be less suitable than the PI3-K/AKT pathway for therapeutic targeting in imatinib-resistant GIST.
JAK and STAT signaling proteins are crucial for BCR-ABL and KIT oncogenic signaling in various models of hematological cancer (Ning et al., 2001 ). In addition, several receptor tyrosine kinases, including epidermal growth factor receptor, MET and PDGFR activate STATs in a JAK-independent fashion (SawkaVerhelle et al., 2000) . STAT1 and STAT3 expression and activation were found in all GIST cell lines studied here ( Figure 3 ) and STAT activation was partially KITdependent in GIST882, GIST48 and GIST430. JAK inhibition by JAK-inhibitor 1 and AG490 silenced STAT activation completely in GIST48 and GIST62, and partially in GIST882 and GIST430: nonetheless, JAK inhibition had no effects on proliferation or apoptosis in any of these cell lines. Therefore, we conclude that STAT activation can be JAK dependent or independent in GIST, and we find no evidence that JAK-dependent STAT activation is crucial to GIST survival or proliferation, in vitro.
In summary, our studies suggest that the PI3-K/AKT pathway is particularly relevant for therapeutic targeting in imatinib-resistant GIST, even in the absence of KIT expression. In contrast to hematological models, neither MAPK nor JAK/STAT pathways seem to play crucial roles in GIST proliferation and survival. Given the minor activity of mTOR inhibitors in our imatinibresistant GIST models, future studies should evaluate inhibitors upstream of mTOR, such as AKT or isoformspecific PI3-K inhibitors.
Materials and methods
Cell lines and reagents GIST882 was established from an untreated, human GIST with a homozygous missense mutation in KIT exon 13 (Tuveson et al., 2001) . GIST430 (primary heterozygous exon 11 in-frame deletion, heterozygous exon 13 missense mutation) and GIST48 (primary exon 11 missense mutation, secondary heterozygous exon 17 missense mutation) were established from GISTs that had progressed -after initial clinical response -during imatinib therapy (Bauer et al., 2006) . GIST62 was derived from an untreated KIT-positive GIST with KIT exon 11 in-frame mutation, but the cell line -despite retaining the activating KIT mutation in all cells -expresses virtually undetectable levels of KIT transcript (data not shown) and protein (Bauer et al., 2005b (Bauer et al., , 2006 .
Reagents
All kinase inhibitors were purchased from Calbiochem (San Diego, CA, USA) except imatinib and RAD001 (everolimus), which were kindly provided by Novartis Institutes for BioMedical Research, Basel, Switzerland. A description of antibodies used in this study can be found in the supplementary information.
In vitro assays Signaling pathway activation profiles were evaluated after exposing confluent GIST cell lines, in serum-free media, to various inhibitors for 4 h. Inhibitors were used, singly or in combinations, at the following final concentrations: imatinib (IM; 1 mM for 4 h studies, 250 nM for proliferation studies), U0126 (U0; 10 mM), LY294002 (LY; 50 mM), RAD001 (RAD; 20 nM), D609 (10 mM), JAK-inhibitor 1 (JAK; 0.1 and 1 mM) and AG490 (AG; 10 and 50 mM).
Cell viability studies were performed using the CellTiter-Glo luminescent assay (Promega, Madison, WI, USA) as described recently (Bauer et al., 2006) . Cell lines were cultured for 1-3 days, and then incubated for 72 h with media containing either kinase inhibitor or dimethyl sulfoxide -only (solvent control) or no treatment. All experimental points were measured in triplicate wells for each plate, and were replicated in at least two plates.
Apoptosis studies were performed by measuring caspase-3 and caspase-7 activation with the caspase-Glo 3/7 Assay Kit (Promega) as described earlier (Bauer et al., 2006) .
Western blotting
Preparation of cell line protein lysates, determination of protein concentrations, electrophoresis and immunoblotting were carried out as described previously (Rubin et al., 2001; Duensing et al., 2004) . Expression levels were normalized using an internal standard, and chemiluminescence signals were captured and quantified using a FUJI LAS1000plus system with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medical Systems, Stamford, CT, USA).
